Tradestie Institutional Equity Comparison Engine
VTAK vs SKIN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SKIN Overall Edge
SKIN Captures Institutional Edge (4โ0 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to The Beauty Health Company Class A Common Stock (SKIN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, VTAK trades at N/M Forward P/E with -388.1% operating margin (+380.7% YoY revenue) versus SKIN at 106.4x Forward P/E and 2.4% operating margin (-2.1% YoY). In options structure, VTAK sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SKIN sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
SKIN
VTAK N/M vs SKIN 106.4x Fwd P/E
Growth & Margin Winner
SKIN
Op Margin -388.1% vs 2.4% ยท YoY +380.7% vs -2.1%
Momentum & Technical Winner
SKIN
1Y -94.3% vs +1057.7% ยท 52W Pos 1% vs 83%
Options & Structure Winner
SKIN
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (100th %ile IV)
VTAK
NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap
$548,639
1M Return
-24.76%
1Y Return
-94.28%
Forward P/E
N/M
Unified AI Score
58.1 / 100
HOLD
Tech 72.0
Fund 70.0
Flow 50.0
Mom 60.0
SKIN
NASDAQ
The Beauty Health Company Class A Common Stock
Surgical & Medical Instruments & Apparatus
$15.05
-7.73% 1D
Market Cap
$106.3M
1M Return
+42.52%
1Y Return
+1057.69%
Forward P/E
106.4x
Unified AI Score
34.1 / 100
SELL
Tech 50.0
Fund 34.0
Flow 67.0
Mom 46.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
VTAK -94.28%
SKIN +1057.69%
Spread: +41.09 pp (SKIN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VTAK Revenue | SKIN Revenue | VTAK Op. Margin | SKIN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $10M | N/A | -498.0% | N/A | VTAK |
| FY2019 | $10M | $170M | -801.9% | 8.1% | SKIN |
| FY2020 | $0M | $120M | -13668.3% | -14.4% | SKIN |
| FY2021 | $0M | $260M | -133027.3% | -15.4% | SKIN |
| FY2022 | $0M | $370M | -192578.6% | -7.1% | SKIN |
| FY2023 | $0M | $400M | -17674.0% | -32.9% | SKIN |
| FY2024 | $0M | $330M | -2676.9% | -20.3% | SKIN |
| FY2025 | $0M | $300M | -2581.6% | -6.9% | SKIN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VTAK | SKIN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $548,639 | $106.3M | Larger Scale | SKIN |
| Trailing P/E Ratio Valuation | N/M | 106.4x | Lower Multiple | SKIN |
| Forward P/E Ratio Valuation | N/M | 106.4x | Lower Multiple | SKIN |
| Revenue Growth (YoY) Growth | +380.7% | -2.1% | Higher Growth | VTAK |
| Operating Margin (TTM) Profitability | -388.1% | 2.4% | Higher Margin | SKIN |
| Net Profit Margin Profitability | 0.0% | -6.3% | Higher Margin | VTAK |
| Return on Equity (ROE) Capital Efficiency | -111.3% | -30.1% | Higher ROE | SKIN |
| 52-Week Range Position Momentum | 1% ($0โ$3) | 83% ($0โ$18) | Stronger Trend | SKIN |
| Beta / 30D Volatility Risk Regime | 0.19ฮฒ ยท 76% Vol | -14.22ฮฒ ยท 192% Vol | Lower Realized Risk | VTAK |
| Unified Institutional Score Composite Signal | 58.1 / 100 (HOLD) | 34.1 / 100 (SELL) | Higher Composite | VTAK |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full VTAK vs SKIN Buy Guide
VTAK
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
SKIN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither VTAK nor SKIN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.